Ganirelix

Ganirelix carries substitutions at positions 1, 2, 3, 6, 8 and 10, including two unusual homoarginine residues that were specifically designed to minimise the histamine release that plagued first-generation GnRH antagonists. Suppression is immediate and dose-dependent, with LH falling roughly 75 percent within 4 hours of a 0.25 mg dose, and it reverses within about 48 hours of the last injection. Clinically it is interchangeable with cetrorelix; the practical differences are formulation - ganirelix comes as a prefilled solution requiring no reconstitution - and price.

Targets: GnRH receptor (GnRHR), Pituitary gonadotrophs, LH surge suppression

• · 0.25 mg in a 0.5 mL prefilled syringe, injected into the thigh or abdomen. No reconstitution required, which is its main practical advantage over cetrorelix.

Work out your exact syringe units →

• very commonInjection-site reaction— Local redness and swelling, usually gone within 4 hours - reported in about a third of patients.
• commonHeadache
• commonNausea
• commonAbdominal pain— Often from the ovarian stimulation rather than the antagonist.
• uncommonOvarian hyperstimulation syndrome— A cycle risk; antagonist protocols reduce but do not eliminate it.
• rareHypersensitivity reaction— Including reports after a first dose.

• Pregnancy and breastfeeding.
• Known hypersensitivity to ganirelix, GnRH or any GnRH analogue.
• Severe renal or hepatic impairment.
• Latex allergy - some prefilled syringe needle covers contain natural rubber latex.

• synergyfollitropin — The standard IVF antagonist protocol pairing.
• redundantcetrorelix — Clinically interchangeable; the choice is about formulation convenience and cost.
• conflictgonadorelin — Direct competitive receptor block.

• · Serial ultrasound follicle tracking and serum oestradiol.
• · LH to confirm surge suppression.
• · OHSS symptoms after trigger.

Prescription drug in the US, EU and most jurisdictions.

• Ganirelix acetate injection prescribing information (label)
• Al-Inany et al. 2016, GnRH antagonists for assisted reproductive technology, Cochrane Database of Systematic Reviews (review)

Ganirelix is competitive antagonism at the pituitary GnRH receptor, and the label's own phrasing is precise: it blocks the receptor on the gonadotroph and the subsequent transduction pathway. No agonist activity, no stored gonadotropin release, no flare. Suppression of LH and FSH is dose-dependent and rapid, and reversal is equally rapid - full recovery of pituitary LH and FSH responsiveness occurs within 48 hours of the last dose. That 48-hour figure is the practically important number, because it is what makes a GnRH agonist trigger possible at the end of an antagonist cycle: the pituitary that has been blocked is still fully functional underneath, waiting, in a way that a downregulated pituitary after weeks of leuprolide is not. Two pharmacokinetic details are worth pulling out. First, ganirelix accumulates modestly with daily dosing - clearance rises from 2.4 to 3.3 litres per hour and terminal half-life from 12.8 to 16.2 hours between single and multiple dosing, with steady state reached in about three days. That is why daily 250 mcg dosing produces steadier suppression as the cycle proceeds rather than a sawtooth. Second, elimination is three-quarters faecal, which means renal impairment matters less here than for most injectable peptides, though it has not been formally studied in that population. The clinical job is narrow and it does it well: prevent the premature LH surge during controlled ovarian stimulation, for the few days when that surge is a threat, then get out of the way.

The failures are cycle-level and timing-driven. Start the antagonist too late and the surge happens anyway; miss a daily injection mid-cycle and the blockade lapses at exactly the wrong moment, because the half-life is only 12 to 16 hours and there is no reservoir. Unlike a depot, there is no forgiveness built into this drug. Injection-site reactions are common, usually a transient wheal, and are more prominent with ganirelix than with some alternatives. Hypersensitivity is rare. Some prefilled products contain benzyl alcohol or are packaged in ways that matter for latex sensitivity, so check the specific presentation. The one thing that does not go wrong is reconstitution, because there is none - the prefilled syringe format removes the mixing error that catches people out with lyophilised cetrorelix.

• GnRH receptor (GnRHR) on pituitary gonadotrophs — High-affinity competitive antagonism; a specific Kd was not resolved here.

  Blocks the receptor and the downstream transduction pathway, producing rapid dose-dependent suppression of LH and FSH with no flare. Full pituitary responsiveness returns within 48 hours of stopping.

• Premature LH surge (the clinical target)

  Prevention of premature luteinisation during controlled ovarian stimulation, protecting the cycle.

• Pituitary reserve (preserved)

  Because the pituitary is blocked rather than desensitised, it can still respond to a GnRH agonist trigger - which is the low-OHSS trigger option that only exists in antagonist cycles.

• Cochrane review: GnRH antagonists for assisted reproductive technology Systematic review · 2016

  Live birth rate and OHSS incidence with antagonist protocols against long agonist protocols. Antagonists showed substantially lower OHSS with comparable live birth rates, which is the evidence base for both ganirelix and cetrorelix.

LH and FSH fall within hours of the first injection, with suppression established the same day. Steady state on daily dosing arrives at about three days, and suppression is steadier late in the antagonist phase than at the start. On stopping, pituitary LH and FSH responsiveness fully recovers within 48 hours, which is the window that makes an agonist trigger possible. The entire drug exposure in a typical IVF cycle is five to eight days.

The standard antagonist protocol is recombinant FSH or human menopausal gonadotropin from cycle day 2 or 3, ganirelix 250 mcg daily added from around stimulation day 5 or 6 or when the lead follicle reaches roughly 14 mm, continued until the trigger. The trigger options are hCG, a GnRH agonist such as leuprolide, or in research settings kisspeptin-54. The agonist trigger deserves emphasis because it is the single most useful thing about antagonist cycles in high-responders: it produces a short endogenous-style surge and dramatically reduces OHSS compared with hCG, and it works only because the pituitary was blocked rather than downregulated. Combining ganirelix with a GnRH agonist depot is self-defeating. Gonadorelin and kisspeptin are pointless against a blocked receptor. Progesterone luteal support is standard after any antagonist cycle and matters more after an agonist trigger because the luteal phase is short.

Against cetrorelix, ganirelix is functionally equivalent in outcomes and differs in the details: slightly higher bioavailability at 91.1 against 85 percent, predominantly faecal rather than biliary elimination, and a prefilled syringe rather than a vial to reconstitute. Cetrorelix offers a 3 mg single-dose option covering about four days that ganirelix does not. Clinics choose on price, supply and habit. Against the leuprolide long protocol, ganirelix compresses weeks of downregulation into days of blockade with no flare, fewer injections and less gonadotropin - the reason antagonist cycles displaced agonist ones. Against degarelix, both are antagonists at the same receptor, but degarelix is a depot built for months of castration in prostate cancer while ganirelix is built for a few days of precise control in a fertility cycle. Same mechanism, opposite design goals.

$150–$700/month. Ganirelix prefilled syringes have commonly run 70 to 150 dollars each in the US, with generics considerably cheaper since patent expiry, and an antagonist cycle uses roughly five to eight. That is a per-cycle cost rather than a monthly one. Figures are indicative and were not verified in this session.

• ?The full amino acid sequence with all unnatural residues was not verified from a primary source in this session, so the sequence fields are left descriptive.
• ?Specific receptor binding affinity values were not resolved.
• ?The time to steady state of about 3 days is inferred from the single-versus-multiple-dose kinetics reported in the label rather than stated directly.
• ?Ganirelix has not been formally studied in renal or hepatic impairment, despite the heavily faecal elimination route suggesting renal impairment should matter less.
• ?Live birth and OHSS effect sizes from the Cochrane review were not extracted numerically in this session.
• ?Cost figures are indicative and were not verified in this session.

• Ganirelix acetate injection - FDA prescribing information DailyMed / FDA

  Source of the 91.1 percent bioavailability, 43.7 L volume of distribution, 81.9 percent protein binding, the single-versus-multiple dose clearance and half-life difference, the 75.1 percent faecal elimination, and the 48-hour recovery of pituitary responsiveness.

• Gonadotrophin-releasing hormone antagonists for assisted reproductive technology Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ, Cochrane Database of Systematic Reviews, 2016 · PMID 27126581

  The systematic review that made antagonist protocols standard. Applies equally to ganirelix and cetrorelix.